In the management of the PAH patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, from the registries, from which the modern risk assessment models have been developed, it is clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there is a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy, and lung transplantation.

In the management of the PAH patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, from the registries, from which the modern risk assessment models have been developed, it is clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there is a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy, and lung transplantation.

In the management of the PAH patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, from the registries, from which the modern risk assessment models have been developed, it is clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there is a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy, and lung transplantation.

In the management of the PAH patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, from the registries, from which the modern risk assessment models have been developed, it is clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there is a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy, and lung transplantation.

In the first-line management of non-small cell lung cancer, the use of immune checkpoint inhibitors (ICI) as monotherapy, as dual ICI, in combination with chemotherapy, or not at all is broadly dependent on which biomarkers are identified. While the choice of therapy is generally based on the level of expression of 1 or more biomarkers (eg, PD-L1, TMB), other factors often complicate this decision. Join us as Drs. Luis Paz-Ares and Kristen Marrone tackle these complexities by providing both foundational and clinical guidance to help you help your patients.

HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limited therapeutic options. Join this lively conversation to enhance your knowledge related to emerging data and optimal treatment selection for patients with HER2-positive gastric and GEJ cancers.

Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.

We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.

There has been considerable clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. The most recent study is the DIAMOND trial, and results were just presented at the American College of Cardiology 2022 meeting. So what does it mean to “enable” RAASi therapy, and how does this impact outcomes for our patients with heart failure? Join our experts as they discuss the value of these trial results and the body of clinical evidence for use of potassium binders in the management of hyperkalemia in patients with heart failure.

Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.

In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment.

If you would like to view the second part of this series, please click here.

Note: after the launch of this activity, lecanemab received accelerated approval by the US Food and Drug Administration for the treatment of AD in patients with MCI or mild dementia.